S13 Ep13: T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD

from OncLive® On Air · host OncLive® On Air

In today’s episode, we spoke with Paolo Tarantino, MD, about key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

Episode metadata supplied by the publisher feed · Published Jun 11, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

S13 Ep13: T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD

0:00 14:41

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 14 minutes long.

This episode was published on June 11, 2025.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!